Search results for "Neurodegenerative"
showing 4 items of 204 documents
SOLID LIPID NANOPARTICLES (SLNs) CONTAINING FERULIC ACID AGAINST OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
2008
Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases.
2022
Vitamin D is a steroid hormone regulating calcium-phosphorus homeostasis, immune response and brain function. In the past thirty years, an increasing number of cohort studies, meta-analyses and randomized controlled trials (RTCs) evaluated the serum levels of 25-hydroxyvitamin D [25(OH)D], which is considered the Vitamin D status biomarker, in patients affected by neurological, psychiatric and autoimmune diseases. Although an association between low 25(OH)D serum levels and the prevalence of these diseases has been found, it is still unclear whether the serum 25(OH)D measurement can be clinically useful as a biomarker for diagnosis, prognosis and predicting treatment response in neurodegene…
Protein levels of brain-derived neurotrophic factor in the hippocampus of low/high aerobic capacity rats
2010
Hippocrates and Plato have first documented the connection between a healthy mind and body, during a period which launched analytical thinking and philosophy in Ancient Greece. Modern research has also indicated the contribution of an active lifestyle to enhanced brain performance and decreased incidence of neurodegenerative diseases and mood disorders such as Alzheimer’s disease and depression respectively. This has been hypothesized to emerge through mechanisms which are enhanced by exercise and contribute on brain plas-ticity and health. The Neurotrophins hypothesis implicates several molecules in brain plasticity and healthy aging. Among them, Brain-derived Neurotrophic Factor (BDNF) ha…
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial
2022
Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods: This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebul…